LAWRENCE, Mass., Oct. 17, 2013 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced the launch of a new educational booklet that outlines the documented benefits and risks of home and more frequent home hemodialysis therapy. The booklet, entitled LIVE, is designed to be used by nephrologists, treatment modality educators, and dialysis providers to educate kidney patients on more frequent home hemodialysis. According to a survey conducted by the American Association of Kidney Patients and published in 2011, only about a third of dialysis patients reported that they were educated on home hemodialysis.
"The benefits of more frequent hemodialysis at home are clear and compelling, so it is no surprise that our patients consistently tell us that the therapy gives them their lives back," said Joe Turk, President, NxStage Medical, Inc. "We urge everyone – whether you are a kidney patient, you know a kidney patient, or you may come in contact with a kidney patient – to read this booklet. With increased awareness of what could be comes the opportunity to change more lives for the better."
The LIVE booklet is organized into 3 sections – Live Healthier, Live Better, Live Longer – describing the clinical, quality of life and survival benefits reported in connection with home and more frequent hemodialysis, while also explaining the risks and responsibilities. In addition, there are quotes from current patients interspersed throughout the booklet, enhancing each topic with their real-world experience.
The LIVE booklet is available online at http://www.nxstage.com/live-brochure.
About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared for home use by the U.S. Food & Drug Administration (FDA). Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage Pureflow™ SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, at home or on vacation, and at a medically appropriate treatment frequency http://www.nxstage.com/.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2013. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE NxStage Medical, Inc.